Scarica l'app Stockscreener
0.6702
2.87%
-0.0198
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.69
Aprire:
$0.692
Volume 24 ore:
1.05M
Relative Volume:
1.24
Capitalizzazione di mercato:
$27.50M
Reddito:
$1.04M
Utile/perdita netta:
$-67.50M
Rapporto P/E:
-0.3487
EPS:
-1.9222
Flusso di cassa netto:
$-60.67M
1 W Prestazione:
+16.94%
1M Prestazione:
+12.54%
6M Prestazione:
-9.43%
1 anno Prestazione:
-67.47%
Intervallo 1D:
$0.6702
$0.73
Intervallo di 1 settimana:
$0.5347
$0.73
Portata 52W:
$0.43
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Nome
Vistagen Therapeutics Inc
Settore
Industria
Telefono
650-577-3600
Indirizzo
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.6702 | 27.50M | 1.04M | -67.50M | -60.67M | -1.9222 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-17 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-17 | Downgrade | Maxim Group | Buy → Hold |
| 2025-12-17 | Downgrade | Stifel | Buy → Hold |
| 2025-12-17 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-12-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-07 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-07-22 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | Iniziato | Robert W. Baird | Outperform |
| 2021-02-18 | Iniziato | Jefferies | Buy |
| 2021-01-04 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | Iniziato | Maxim Group | Buy |
| 2018-02-08 | Reiterato | Chardan Capital Markets | Buy |
| 2017-03-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Vistagen Therapeutics Inc Borsa (VTGN) Ultime notizie
Vistagen Therapeutics Inc (VTGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Vistagen Therapeutics directors to step down after 2026 annual meeting - Investing.com UK
Vistagen Therapeutics Inc (VTGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Two Vistagen (VTGN) directors will not seek re-election at 2026 shareholder meeting - Stock Titan
Vistagen Therapeutics Inc (VTGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Here's Why Vistagen Therapeutics (NASDAQ:VTGN) Must Use Its Cash Wisely - Sahm
Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth - TipRanks
Vistagen Therapeutics Inc (VTGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vistagen Therapeutics Inc (VTGN) Institutional Confidence - TradingKey
VistaGen Therapeutics (VTGN) Q4 2026 earnings summary - Quartr
VISTAGEN THERAPEUTICS ($VTGN) Releases Q4 2026 Earnings - Quiver Quantitative
vtgn-20260331 - SEC.gov
VTGN: Net loss increased to $69.7M as R&D spending rose, with cash reserves at $45.4M and going concern risk - TradingView
Vistagen (VTGN) outlines Phase 3 fasedienol data and broad intranasal CNS pipeline - Stock Titan
Vistagen Reports FY2026 Net Loss $69.7M; Cash and Marketable Securities $45.4M - TradingView
VTGN: Advanced clinical milestones and maintained cash runway despite increased net loss - TradingView
Vistagen (NASDAQ: VTGN) advances fasedienol trials as FY 2026 loss deepens - Stock Titan
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - Yahoo Finance
Generalized Anxiety Disorder Market: Growth Momentum Across 7MM to 2036 – DelveInsight | VistaGen Therapeutics, Fabre-Kramer Pharm, Mind Med, Sunovion, ChemRar Research, Biohaven Pharma, Forest Lab - Barchart.com
VTGN Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock Edges HigherGuidance vs Actual - newsline.com
VTGN News | VISTAGEN THERAPEUTICS INC (NASDAQ:VTGN) - ChartMill
Vistagen Therapeutics (VTGN) Edges Higher Amid Cautious TradingRVOL Breakout - newsline.com
Vistagen (VTGN) Achieves Key Milestone in Social Anxiety Disorder Treatment - GuruFocus
Vistagen achieves ICH E1 safety exposure milestones for fasedienol; >1,500 subjects exposed - TradingView
Vistagen (VTGN) reaches ICH safety exposure goal in Phase 3 fasedienol program - Stock Titan
Vistagen meets ICH E1 safety exposure targets for fasedienol By Investing.com - Investing.com Australia
Nasal spray for social anxiety clears key safety bar in 1,500 people - Stock Titan
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm - GuruFocus
Vistagen Stock at 63 Cents: The June Trial Readout Traders Are Watching - Bez Kabli
VTGN Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost DisciplineEPS Revision Trend - The Legal Advocate
Vistagen (VTGN) Prepares for Jefferies Healthcare Conference Ami - GuruFocus
Vistagen (VTGN) Prepares for Jefferies Healthcare Conference Amid Key Trial Updates - GuruFocus
Investor meetings as Vistagen joins Jefferies 2026 healthcare event in NYC - Stock Titan
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference - Yahoo Finance
Vistagen Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Vistagen Therapeutics (VTGN) Holds Near Support After Minor DeclineBullish Sentiment - The Legal Advocate
Vistagen Therapeutics (VTGN) Shows Modest Gain Amid Tight Trading RangeWave Equality - The Legal Advocate
Vistagen Therapeutics (VTGN) Q1 2026 Earnings: Narrowing Loss Beats Estimates as Pipeline Progress ContinuesExpert Market Insights - Newser
VTGN Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressEarnings Call Highlights - newsline.com
VTGN Q1 2026 Earnings: Narrower-than-Expected Loss as Vistagen Advances Pipeline, Stock Edges LowerSubscription Growth Report - The Legal Advocate
VistaGen Appoints New Chief Medical Officer to Advance Pipeline - The Globe and Mail
VTGN: Fasedienol nears pivotal phase III data in SAD, with pipeline progress and cash runway into 2027 - TradingView
Vistagen Therapeutics (VTGN) Stock: Up +0.98%, Key Resistance at $0.67 2026-05-20Bull Flag - The Legal Advocate
[Form 4] Vistagen Therapeutics, Inc. Insider Trading Activity - Stock Titan
[Form 3] Vistagen Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Vistagen (VTGN) hires Angel S. Angelov, MD, MBA as Chief Medical Officer with option grant - Stock Titan
VTGN DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class ActionVTGN - TMX Newsfile
Vistagen appoints Angel S. Angelov as chief medical officer - marketscreener.com
Vistagen appoints Angel Angelov as chief medical officer By Investing.com - Investing.com Australia
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer - Yahoo Finance
Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results? - Insider Monkey
Vistagen Therapeutics Inc Azioni (VTGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):